Adam Gridley

Adam Gridley is the Chief Executive Officer of Allay Therapeutics, a company focused on developing innovative analgesic products aimed at improving post-surgical pain management. He has held this position since September 2020 and is based in the San Francisco Bay Area. Under his leadership, Allay Therapeutics is pioneering ultra-sustained analgesic solutions, which are designed to enhance recovery for patients and streamline pain management for healthcare providers.1

Professional Background

Gridley boasts over 25 years of experience in various leadership roles within the biotech and healthcare industries. Before joining Allay Therapeutics, he served as the CEO of Entera Bio Ltd. for over a year and held multiple executive positions at Histogenics Corporation, including President and Interim President.1 Additionally, he has extensive experience in corporate development and operations from his time at Merz North America and BioForm Medical, Inc..1

Education

He earned a Bachelor of Science degree and an MBA from the University of Denver, completing his studies in the mid-1990s.1

Current Roles

In addition to his role at Allay Therapeutics, Gridley is also the Executive Chairman of LifeSprout and serves on its Board of Directors, reflecting his ongoing commitment to advancing healthcare solutions.1

Adam Gridley's extensive background in operational leadership and product development positions him as a significant figure in the biotechnology sector, particularly in pain management innovations.